Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

NCT07009470 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07009470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07009470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
Lead sponsor
Tongji Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 10, 2025
Completion date
October 28, 2028
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc